Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study

Norio Hayashi, Niloufar Mobashery, Namiki Izumi, Norio Hayashi, Niloufar Mobashery, Namiki Izumi

Abstract

Background: Vaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases virologic response rates in HCV genotype (GT) 1-infected patients when added to peginterferon and ribavirin (PR).

Methods: This was a phase II, multicenter, double-blind, randomized, dose-ranging study in Japanese patients with HCV GT1 infection and previous relapse. Patients received twice daily vaniprevir 100, 300, or 600 mg, or placebo plus PR for 4 weeks then PR alone for 2 weeks. Further treatment with PR was continued up to a maximum of 72 weeks. The primary endpoint was rapid virologic response (RVR; undetectable HCV RNA at treatment week 4).

Results: Ninety patients completed 4 weeks of vaniprevir/placebo plus PR. Rates of RVR were significantly higher with vaniprevir compared with placebo (86, 95, and 76 % in the vaniprevir 100-, 300-, and 600-mg arms versus 20 % with control; p<0.001 for all comparisons). Rates of SVR, an exploratory analysis, in the vaniprevir 100-, 300-, 600-mg, and control arms were 95, 100, 100, and 72 %, respectively. No patient had virologic breakthrough or non-response while receiving vaniprevir. There were no serious adverse events (AEs) or discontinuations due to an AE during vaniprevir treatment. Diarrhea and nausea were more common with vaniprevir 600 mg than control or lower vaniprevir doses.

Conclusion: The addition of vaniprevir to PR was associated with an increase in RVR and SVR. Combined with a generally safe and well-tolerated profile, these data supported the further evaluation of vaniprevir in Japanese patients with HCV GT1 infection (#NCT00880763).

Figures

Fig. 1
Fig. 1
Patient disposition. AE adverse event, bid twice daily, PR peginterferon alfa-2a and ribavirin
Fig. 2
Fig. 2
Rapid virologic response. PR peginterferon alfa-2a and ribavirin, RVR rapid virologic response (undetectable HCV RNA at treatment week 4). *p < 0.001 versus PR control
Fig. 3
Fig. 3
Mean decline in HCV RNA from baseline to week 6. bid twice daily, PR peginterferon alfa-2a and ribavirin. *Administered with peginterferon alfa-2a and ribavirin
Fig. 4
Fig. 4
Sustained virologic response. PR peginterferon alfa-2a and ribavirin, SVR sustained virologic response (undetectable HCV RNA 24 weeks after completing last dose of treatment)
Fig. 5
Fig. 5
Change from baseline laboratory observations during vaniprevir therapy: a alanine aminotransferase; b aspartate aminotransferase; c bilirubin; d hemoglobin. bid twice daily, PR peginterferon alfa-2a and ribavirin. *Administered with peginterferon alfa-2a and ribavirin

References

    1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53(1):39–43. doi: 10.1159/000252782.
    1. Guidelines for the management of hepatitis C virus infection: first edition, May 2012, the Japan Society of Hepatology. Hepatol Res. 2013;43(1):1–34. doi: 10.1111/hepr.12020.
    1. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138–147. doi: 10.1007/s00535-013-0875-1.
    1. McCauley JA, McIntyre CJ, Rudd MT, et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J Med Chem. 2010;53(6):2443–2463. doi: 10.1021/jm9015526.
    1. Olsen DB, Davies ME, Handt L, et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother. 2011;55(2):937–939. doi: 10.1128/AAC.00990-10.
    1. Liverton NJ, Carroll SS, Dimuzio J, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother. 2010;54(1):305–311. doi: 10.1128/AAC.00677-09.
    1. Lawitz E, Sulkowski M, Jacobson I, et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Res. 2013;99(3):214–220. doi: 10.1016/j.antiviral.2013.05.015.
    1. Manns MP, Gane E, Rodriguez-Torres M, et al. Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase 2 study. Hepatology. 2012;56(3):884–893. doi: 10.1002/hep.25743.
    1. Lawitz E, Rodriguez-Torres M, Stoehr A, et al. A phase 2b study of Mk-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol. 21 Feb 2013.
    1. Rodriguez-Torres M, Stoehr A, Gane EJ, et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of sustained viral response in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol. 2014;12(6):1029–1037. doi: 10.1016/j.cgh.2013.09.067.
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213–226. doi: 10.1002/sim.4780040211.
    1. Liang K-Y, Zeger SL. Longtitudinal data analysis using generalized linear models. Biometrika. 1986;73(1):13–22. doi: 10.1093/biomet/73.1.13.
    1. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol. 2011;55(1):192–206. doi: 10.1016/j.jhep.2011.01.011.
    1. Barnard RJ, McHale CM, Newhard W, et al. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology. 2013;443(2):278–284. doi: 10.1016/j.virol.2013.05.013.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe